# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Lake Street analyst Frank Takkinen initiates coverage on Pulmonx (NASDAQ:LUNG) with a Buy rating and announces Price Target ...
Canaccord Genuity analyst Jon Young maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $16 to $15.
ALLR: 151% | Allarity Therapeutics shares are trading higher after the company announced that Stenoparib shows a clear clinical...
Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.46) by 21...
Piper Sandler analyst Jason Bednar reiterates Pulmonx (NASDAQ:LUNG) with a Overweight and maintains $17 price target.